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ABSTRACT
Introduction: Dimethyl fumarate (DMF) is a
novel oral therapy used for the treatment of
relapse-remitting multiple sclerosis (RRMS). In
two 2-year pivotal Phase 3 trials in patients with
RRMS, DMF significantly reduced disease
activity based on both clinical and magnetic
resonance imaging (MRI) findings and
demonstrated an acceptable safety profile.
However, there is currently a lack of
comparative data which explore the
relationship between work productivity and
health-related quality of life (HRQoL)
outcomes in RRMS and how these differ
among RRMS therapies, including DMF.
Methods: We explored this relationship
through patient-reported data from the
EuroQol Five-Dimensions (EQ-5D) tool, Work
Productivity and Activity Impairment
Questionnaire (WPAI), and the Hamburg
Quality of Life Questionnaire in Multiple
Sclerosis (HAQUAMS) using the Adelphi MS
DSP dataset.
Results: Our data demonstrated that patients
receiving DMF experienced better outcomes,
relative to patients receiving beta
(b)interferons or glatiramer acetate, in all
WPAI subscales [overall; average treatment
effect (ATE) -13.92, 95% confidence interval
(CI) -18.87 to -7.08; p\0.001], EQ-5D (ATE
?0.075, 95% Cl 0.014–0.136; p = 0.016) and
HAQUAMS [ATE -0.45, 95% Cl -0.61 to
-0.29; p\0.001]. The EQ-5D and HAQUAMS
were used with WPAI to determine the
relationship between HRQoL outcomes and
work productivity. Multiple linear regression
analyses were performed, adjusting for age, sex,
body mass index, ethnicity and number of
comorbid conditions.
Conclusions: These data demonstrate that
therapy with DMF was associated with
increased work productivity and HRQoL for
patients with RRMS and that these outcomes
were consistently improved compared to
outcomes with interferon and glatiramer
acetate therapies.
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Multiple sclerosis (MS) is a chronic, progressive
demyelinating disease of the central nervous
system [1] that affects approximately 2.1
million people worldwide (90 per 100,000
population in the USA [2]). A range of
neurological symptoms are associated with
MS, including spasticity, pain, ataxia, tremor,
fatigue, weakness, cognitive effects, and
depression [3]. The predominant clinical
presentation of MS, diagnosed in 85% of
patients, is the relapsing-remitting variant
(RRMS), which is defined by periods of
symptomatic flares interspersed by periods of
relative stability [4]. Approximately 70% of
patients with RRMS will develop progressive
neurological decline described as secondary
progressive MS [5]. Periods of symptomatic
flares associated with RRMS patients may remit
partially or completely following a relapse, and
the various functional impairments associated
with these flares have been shown to have a
detrimental effect on a patient’s health-related
quality of life (HRQoL) [6].
Currently available treatments include
therapies with beta (b) interferons (including
Avonex, Rebif, Betaseron, and Extavia) and
glatiramer acetate (Copaxone), collectively
referred to as ABCREs, newer oral agents, and
monoclonal antibodies [7]. There is no cure for
MS, and as a result of the typical onset of MS in
young adults [8], patients often require life-long
treatment, which can result in increasingly
complex therapy decisions over the patient’s
lifetime [9]. For example, approximately
two-thirds of patients receiving ABCRE therapy
have to switch to an alternative therapy due to
the lack of efficacy [9], persistent disease activity,
or occurrence of an adverse event [10]. However,
the ABCRE therapies have the advantage ofmore
than 20 years of safety data being available [7].
Since the approval of orally administered
therapies, extensive uptake as both a first- and
second-line option has been observed [11].
Dimethyl fumarate (DMF) (Tecfidera) is a
novel oral therapy for RRMS [12]. Its
mechanism of action is believed to be through
activation of the nuclear erythroid 2-related
factor 2 (Nrf2) transcriptional pathway to exert
neuroprotective effects [13, 14], thereby slowing
disease progression and neuro-inflammation
[15]. In addition, DMF has
immunomodulatory effects which help reduce
inflammation. Phase III clinical trials have
demonstrated significant reductions in annual
relapse rates of approximately 50% over 2 years
[16] and a greater reduction of T2 lesions when
compared to the existing therapy with
glatiramer acetate [16]. Ad hoc analysis of the
DEFINE/CONFIRM clinical trials showed
increased efficacy in DMF patients compared
to placebo patients across multiple end-points,
including cognitive impairment [17], no
evidence of disease activity [18], HRQoL
outcomes [19], slower disability progression,
and overall disease burden [20]. Evidence
suggests that DMF has greater efficacy than
ABCRE therapies [7], but how this efficacy
translates into work productivity benefits has
yet to be studied.
The DEFINE clinical trial demonstrated
better HRQoL outcomes in patients in the
DMF arm versus those in the placebo arm [19].
A significant correlation between presenteeism
and reduced quality of life in MS patients has
been demonstrated [21], but there remains a
need for further comparisons of HRQoL and
overall work productivity outcomes between
patients on DMF and ABCRE therapy.
The aim of this study was to assess the
impact of RRMS therapies on work productivity
and HRQoL outcomes. To this end, we
compared ABCRE therapies and DMF in terms
of HRQoL and work productivity outcomes
among RRMS patients. As work productivity
remains an important factor for payers to
consider, HRQoL outcomes were investigated
as a predictor of work productivity.
METHODS
Data were drawn from the Adelphi Real World
MS IV Disease Specific Programme (DSP) (2014/
2015). The Adelphi MS DSP is a real-world,
cross-sectional, survey of neurologists and their
MS patients across the USA and Europe. The full
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methodology, including limitations, has been
published [22]. The study is based on the
completion of detailed patient record forms by
physicians and a self-completed questionnaire
by patients and caregivers.
Our study was based on previously
conducted studies and did not involve any
new studies of human or animal subjects
performed by any of the authors. The research
was conducted in full accordance with the U.S.
Health Insurance Portability and Accountability
Act 1996 (http://www.hhs.gov/ocr/privacy/).
All data were collected through local fieldwork
partners and fully de-identified prior to receipt
by Adelphi.
Study Population
Participating physicians were asked to recruit
their next eight consecutive consulting patients
who met the eligibility criteria. All patients in
the DSP patient sample required a formal
diagnosis of RRMS and had to be[18 years of
age. Of all patients captured in the database,
RRMS patients on either DMF or another
therapy, including ABCRE therapy, with a
current treatment duration of [12 months
were included in the analysis. A total of 828
RRMS patients on either DMF or ABCRE
therapies were recruited, among whom 260
patients provided data for inclusion in the
analysis on HRQoL outcomes (the HRQoL
sample). Of these 260, 160 patients provided
sufficient data for inclusion in the analysis on
work productivity (the Work Productivity
sample). Sample sizes for each patient-recorded
outcome (PRO) and subscale can be found in
Table 3.
Data Collection
Data were collected using patient
self-completion forms (PSCs). These PSCs
provided information on patient HRQoL
outcomes, measured using the EuroQol
Five-Dimensions (EQ-5D) health states and
visual analog scale (VAS) [23, 24], and the
Hamburg Quality of Life Questionnaire in
Multiple Sclerosis (HAQUAMS) [25], and on
work productivity, which was measured using
the Work Productivity and Activity Impairment
Questionnaire (WPAI) [26].
EQ-5D is a generic multi-attribute
health-state classification system which
assesses HRQoL in five dimensions, i.e.,
mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression, using
three levels, namely, no problems, some
problems, and severe problems, respectively.
Scores are reported on a 0 (dead) to 1 (full
health) scale to represent preferences for a
person’s health state. The EQ-5D also uses a
VAS to rate an individual’s health state on a
scale from 0 to 100, with 0 being the worst
health state imaginable and 100 being the best
health state imaginable. The EQ-5D scale ranges
from 0 to 1, with a higher score indicating a
better HRQoL outcome.
The WPAI consists of six items across four
domains: absenteeism (work time missed),
presenteeism (impairment at work/reduced
on-the-job effectiveness), work productivity
loss (overall work impairment/absenteeism ?
presenteeism), and activity impairment. Each
domain is measured on a scale of 0–100% in
terms of levels of impairment. The WPAI items
include currently employed (Q1); hours missed
due to health problems (Q2); hours missed for
other reasons (Q3); hours actually worked (Q4);
degree that health affected productivity while
working (on a 0–10 VAS) (Q5); degree that
health affected productivity in regular unpaid
activities (0–10 VAS) (Q6). The recall period is 7
days. A lower score on the WPAI subscales
indicates an improvement in work productivity.
The HAQUAMS is a 38-item, MS-specific
quality of life self-assessment tool consisting of




mood; handicap; general health. Each domain
is measured on a 5-point scale with 1 being
‘much better’ and 5 being ‘much worse’.
Specific domains (i.e., not general health) have
a recall period of 7 days. A low score in the
HAQUAMS indicates better outcomes.
In addition to the PRO measures (t), patient
demographic data, including age, sex, body
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mass index (BMI), ethnicity, gender, work status
and type, and marital status, were collected. The
Expanded Disability Status Scale (EDSS), a
method used to quantify disability in MS and
to monitor changes in disability levels over
time, was also included [27]. No tests or
investigations were required/conducted for a
patient to be included in the study.
Statistical Analysis
Kruskal–Wallis, Fisher’s Exact, and Chi-squared
tests were used to examine differences in
demographics between patients receiving DMF
therapy and those receiving ABCREs.
Propensity scores were generated using EDSS
scores at initiation of current treatment, age, sex,
BMI, duration of current treatment, line of
therapy (by how many lines of therapy the
patient has received), time since diagnosis, and
number of comorbid conditions. Estimated
average treatment effects (ATEs) of DMF
therapy versus ABCRE therapies were generated
by using the propensity score to weight
regressions [inverse-probability-weighted
regression-adjustment (IPWRA)]. Due to the
observational nature of the data, any significant
difference in an outcome (using a bivariate test)
between the two groups may be due to
confounding factors. To address this issue of
confounding factors, we used IPWRA in an
attempt to balance the pre-specified covariates
(including EDSS at initiation) between the study
group and control group through the use of
inverse probability weights (inverse of the
propensity score), estimated using a logistic
regression model. The weighting serves to
weight both the study group and control group
up to the full sample. This balancing of
pre-specified covariates is made so that
differences in outcome will not be
overestimated due to differences in the
covariates among groups. IPWRA is a
doubly-robust method, which means it will
yield accurate treatment effect estimates if
either the propensity score model or the
outcome model is correctly specified.
To demonstrate the relationship between
HRQoL outcomes and work productivity, we
performed multiple linear regression analyses,
adjusting for age, sex, BMI, ethnicity, and
number of comorbid conditions.
RESULTS
Patients who provided data on both HRQoL and
WPAI outcomes were included in the regression
analyses to explore the relationship between the
two outcomes. The baseline demographics of
the patient sample are shown in Table 1.
The total sample included almost twofold
more female than male respondents, but this
ratio not differ significantly between the two
treatment groups (DMF therapy 30% male, 70%
female vs. ABCRE therapies 31% male, 69%
female) or the HRQoL and work productivity
outcome groups (DMF therapy 39% male, 61%
female vs. ABCRE therapies 30% male, 70%
female). Compared with patients on DMF
therapy, there was little difference in the mean
age of patients receiving ABCREs (work
productivity sample: 36.83 vs. 36.15 years,
p = 0.686; HRQoL sample: 36.97 vs.
37.51 years, p = 0.791) or in mean years
diagnosed (work productivity sample: 4.44 vs.
5.05 years, p = 0.263; HRQoL sample: 5.03 vs.
5.73 years, p = 0.108). There was a difference in
the ethnicity profile between DMF patients and
ABCRE patients (p\0.001).
WPAI: Work Productivity Loss
Patients were largely in full-time employment
across all comparator groups (work productivity
sample: DMF therapy 91.30% vs. ABCRE
therapies 75.18%, p = 0.622; HRQoL therapies:
DMF 77.42% vs. ABCRE therapies 55.02%,
p = 0.267) (Table 2), and no significant
difference was observed between the
comparator groups in the HRQoL or work
productivity sample or the subgroups of
patients receiving DMF versus ABCRE
therapies. The most common type of work was
professional or skilled (work productivity
subscale: 78.26 vs. 79.67%, p[0.999; HRQoL
sample: 74.07 vs. 77.48%, p = 0.588) with no
significant difference observed between the two
Neurol Ther
Table 1 Patient demographics and clinical characteristics










Age (years) 36.83 ± 8.61 36.15 ± 8.49 0.686 36.97 ± 10.36 37.51 ± 9.74 0.791
Years diagnosed 4.44 ± 3.35 5.05 ± 3.65 0.263 5.03 ± 5.13 5.73 ± 4.47 0.108
Gender [0.999 0.307
Male 7 (30.43) 43 (31.39) 12 (38.71) 68 (29.69)
Female 16 (69.57) 94 (68.61) 19 (61.29) 161 (70.31)
Ethnicity 0.001 \0.001
White/Caucasian 16 (69.57) 124 (90.51) 22 (70.97) 208 (90.83)
African American/
Afro-Caribbean
5 (21.74) 4 (2.92) 7 (22.58) 8 (3.49)
Hispanic/Latino 0 (0) 5 (3.65) 0 (0) 8 (3.49)
Other 2 (8.70) 4 (2.92) 2 (6.45) 5 (2.18)
Body mass index 25.47 ± 4.31 24.39 ± 3.68 0.225 26.64 ± 5.06 25.19 ± 4.45 0.076
Housing status 0.324 0.097
Lives alone 5 (21.74) 15 (10.95) 8 (25.81) 27 (11.79)
Lives with partner/
spouse
16 (69.57) 104 (75.91) 19 (61.29) 162 (70.74)
Lives with other
family/friends
2 (8.70) 18 (13.14) 4 (12.90) 40 (17.47)
Dependents 0.821 [0.999
Dependents 12 (52.17) 78 (56.93) 16 (51.61) 118 (51.53)
No dependents 11 (47.83) 59 (43.07) 15 (48.39) 111 (48.47)
Relationship status 0.536 0.304
Married/long term
relationship
17 (73.91) 114 (83.21) 20 (64.52) 176 (76.86)
Divorced/separated 1 (4.35) 5 (3.65) 2 (6.45) 12 (5.24)
Single 5 (21.74) 18 (13.14) 9 (29.03) 41 (17.90)
EDSS at treatment
initiation
1.07 ± 0.98 1.66 ± 1.17 0.024 1.55 ± 1.68 1.94 ± 1.42 0.049
Duration of current
treatment (years)
1.78 ± 0.79 3.82 ± 3.10 \0.001 1.65 ± 0.73 4.22 ± 3.49 \0.001
Lines of therapy 1.74 ± 0.75 1.24 ± 0.46 \0.001 1.74 ± 0.77 1.25 ± 0.48 \0.001
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patient groups (Table 2). Patients receiving
ABCRE therapies were more likely to have
retired or left work as a result of their MS than
those receiving DMP therapy: 45.45% of all
non-working ABCRE patients stated they
retired/left work because of their MS compared
to none of the DMF patients (work productivity
sample) (Table 2).
WPAI: All subscales
The ATEs for WPAI subscales were estimated in
patients receiving DMF therapy versus those
receiving ABCRE therapies. Patients receiving
DMF therapy were associated with better WPAI
scores with ATEs of -13.92 (p\0.001) and
-17.26 (p\0.001) in overall work impairment
and activity impairment subscales, respectively
(Table 3; Fig. 1). Patients receiving DMF therapy
were also associated with better absenteeism
and presenteeism subscale scores than ABCRE
patients (absenteeism: ATE = -2.06, p = 0.012;
presenteeism -12.97, p\0.001).
An ATE of 0.075 (p = 0.016) in the EQ-5D
tool and 10.84 (p B 0.001) in the EQ-VAS was
observed in patients receiving DMF compared
to ABCRE patients (Table 3; Fig. 1).
Relationship Between Overall Work
Impairment Subscale and HRQoL
Regression analyses using the EQ-5D and
HAQUAMS to predict the WPAI overall work
impairment subscale were performed.
Increasing EQ-5D scores were significantly
associated with a decreasing score on the
WPAI overall work impairment subscale
(Table 4), demonstrating that for an
improvement of 0.1 on the EQ-5D scale, an
improvement of 6.42% (95% Cl -8.32 to -4.52;
p\0.001) can be predicted on the WPAI overall
work impairment subscale scale. An
improvement in the HAQUAMS score of -1.0
was similarly associated with an improvement
in the WPAI overall work impairment subscale
of 22.44% (95% Cl 18.11–26.77, p\0.001)
(Table 4). A lower HAQUAMS score indicates
better HRQoL outcomes; therefore, the data
demonstrate that a reduction of 1 point on the
HAQUAMS scale leads to an reduction of WPAI
overall work impairment by -22.44% on the
WPAI overall work impairment subscale. The
regression analysis using HAQUAMS and EQ-5D
to predict WPAI was plotted to demonstrate
that as HRQoL improves, so does work
productivity (Fig. 2).
DISCUSSION
The results of this real-world survey of MS
patients demonstrate that those receiving DMF
therapy experienced higher HRQoL and work
productivity than those receiving ABCRE
therapy. Among our patient cohort, those
receiving DMF use was associated with better
outcomes, including overall work impairment,
absenteeism, presenteeism, activity
impairment, EQ-5D, and HAQUAMS.
Regression analyses of these outcomes were
subsequently used to predict work productivity
as a function of HRQoL [21]. Regression analysis
of the EQ-5D and HAQUAMS scores
Table 1 continued












0.17 ± 0.49 0.38 ± 1.00 0.466 0.23 ± 0.56 0.41 ± 0.99 0.370
Values in table are reported as the number with the percentage in parenthesis or as the mean ± standard deviation (SD)
DMF, Dimethyl fumarate; ABCRE, therapies for multiple sclerosis involving beta (b) interferons (including Avonex, Rebif,

























































































































































































































































































































































































































































































































































































































demonstrated the relationship between HRQoL
and work productivity outcomes, revealing that
as Qol measured by HAQUAMS improved by a
single point, the corresponding WPAI score also
improved by 22.44% and that as EQ-5D
increased by 0.1 (i.e., an improvement), WPAI
again improved, in this case by 6.42%.
Full-time employment was lower in ABCRE
patients for both the work productivity sample
and the HRQoL sample (Table 2). Patients not in
full-time employment were asked if this was a
due to their MS, but no significant differences
were observed in the responses between
patients receiving DMF or ABCRE therapies.
The ATE was used as a measure of how receiving
DMF may impact various outcomes. Our
research demonstrates that both absenteeism
and presenteeism were improved in patients
receiving DMF therapy compared to those
receiving ABCRE therapies. This result
highlights that not only were patients less
likely to miss work as a result of receiving
DMF (absenteeism) but that work impairment
was reduced while at work (presenteeism). This
finding was fortified by results indicating that
both overall work impairment and activity
impairment were significantly reduced in
patients receiving DMF compared to those
receiving ABCREs. ATEs for absenteeism and
presenteeism in those receiving DMF were
associated with improvements compared to
those receiving ABCRE therapies, highlighting
a better WPAI outcome for DMF patients.
DMF patients had significantly higher
HRQoL scores for both the EQ-5D and
HAQUAMS. These data are in line with results
from published studies [7, 19, 28], but while
these published results are from a clinical trial
setting using a placebo control group, we have
been able to demonstrate a comparison against
ABCRE patients in the real-world setting.
Further, we have been able to demonstrate,
Table 3 Inverse-probability-weighted regression-adjustment analyses
of patient-reported data from the EuroQol Five-Dimensions tool,
Work Productivity and Activity Impairment Questionnaire, and the
Hamburg Quality of Life Questionnaire in Multiple Sclerosis
comparing ABCRE therapies and DMF therapy
Outcome Base
(n)
ABCRE therapy DMF average treatment
effect
p value
WPAI: percentage work time missed
(absenteeism)
154 2.06 (0.46–3.67) -2.06 (-3.67 to -0.46) 0.012
WPAI: percentage work time impaired
(presenteeism)
158 19.45 (16.26–22.64) -12.97 (-18.87 to -7.08) \0.001
WPAI: percentage overall work impairment 152 20.92 (17.38–24.46) -13.92 (-19.86 to -7.98) \0.001
WPAI: percentage activity impairment 243 25.31 (21.99–28.63) -17.26 (-23.50 to -11.03) \0.001
EQ-5D 255 0.823 (0.793–0.852) 0.075 (0.014 to 0.136) 0.016
EQ-VAS 252 74.55 (72.54–76.55) 10.84 (6.15 to 15.53) \0.001
HAQUAMS fatigue/thinking subscale 245 1.90 (1.77–2.03) -0.47 (-0.75 to -0.19) 0.001
HAQUAMS mobility/lower limb subscale 233 1.84 (1.72–1.95) -0.43 (-0.75 to -0.11) 0.009
HAQUAMS mobility/upper limb subscale 247 1.38 (1.30–1.46) -0.15 (-0.32 to 0.02) 0.075
HAQUAMS social function subscale 248 2.05 (1.96–2.15) -0.54 (-0.77 to -0.31) \0.001
HAQUAMS mood subscale 250 2.40 (2.28–2.53) -0.45 (-0.64 to -0.26) \0.001
HAQUAMS total 227 1.95 (1.86–2.04) -0.45 (-0.61 to -0.29) \0.001
EQ-5D, EuroQol Five-Dimensions tool; WPAI, Work Productivity and Activity Impairment Questionnaire; HAQUAMS,
Hamburg Quality of Life Questionnaire in Multiple Sclerosis comparing ABCRE therapies and DMF therapy
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using regression analysis, how improvements in
work productivity and activity impairment are
associated with improved HRQoL outcomes
(Table 4). When we considered specific
components of the HAQUAMS subscale, such
as fatigue, social function, mood, and mobility,
we observed improvements across all subscales
in DMF patients compared to ABCRE patients
(Table 3). In addition to the outcomes collected,
we have generated a WPAI overall work
impairment predictor as a function of the
HRQoL outcomes, EQ-5D and HAQUAMS
(Table 4; Fig. 2). We observed that a better
HRQoL score was significantly associated with
Fig. 1 Graphical representation of data from the
inverse-probability-weighted regression-adjustment analy-
ses presented in Table 2 on patients with multiple sclerosis
started on ABCRE therapies vs. DMF therapy. Data
include scores for the Work Productivity and Activity
Impairment Questionnaire and quality of life measures.
ABCRE Therapy involving b interferons (including
Avonex, Rebif, Betaseron, and Extavia) and glatiramer
acetate (Copaxone), DMF dimethyl fumerate therapy,
ATE average treatment effect
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a better WPAI overall work impairment score,
and we have proved this association using two
separate HRQoL measures. This is a significant
finding as we have demonstrated this
relationship using two independently
validated HRQoL tools to highlight the
relationship between HRQoL and the WPAI
overall work impairment subscale in MS
patients. A reduced HRQoL score was
associated with an increase in work and
activity impairment, highlighting that the
costs associated with work and activity
impairment are likely to be higher for those
with poor HRQoL outcomes. This relationship is
important to consider as HRQoL outcomes have
been demonstrated to affect work and activity
impairment outcomes.
The limitations of this study include the
small population size. The respondent rate for
patients receiving DMF therapy was lower than
that of patients receiving ABCRE therapies.
When patients were recruited to the study,
they were not recruited based on the
treatment they received (i.e., we did not
recruit 50% of the sample on DMF and the
other 50% on ABCREs); therefore, the difference
in sample sizes between the two patient groups
is more representative of the real-world setting
from which they were recruited. A further
general concern is that the propensity score is
Table 4 Regression relationship of Work Productivity and Activity Impairment Questionnaire scores with those of the
EuroQol Five-Dimensions tool and Hamburg Quality of Life Questionnaire in Multiple Sclerosis questionnaire
Independent variable EQ-5D p value HAQUAMS p value
EQ-5D -64.25 (-83.23 to -45.27) \0.001 – –
HAQUAMS – – 22.44 (18.11 to 26.77) \0.001
Age -0.26 (-0.56 to 0.04) 0.083 -0.15 (-0.41 to -0.11) 0.255
Male 3.13 (-2.55 to 8.81) 0.278 4.24 (-0.78 to 9.26) 0.097
Body mass index 0.20 (-0.55 to 0.94) 0.601 0.09 (-0.59 to 0.76) 0.800
Comorbidities 3.02 (0.15 to 5.89) 0.040 0.26 (-2.34 to 2.87) 0.843
Regressions use the EQ-5D and HAQUAMS measures to predict overall work impairment by the Work Productivity and
Activity Impairment Questionnaire, after adjusting for age, sex, body mass index and number of comorbid conditions
Fig. 2 Regression of Work Productivity and Activity Impairment Questionnaire with EuroQol Five-Dimensions (EQ5D)
and Hamburg Quality of Life Questionnaire in Multiple Sclerosis Questionnaire (HAQUAMS)
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generated using specified variables, and hidden
bias may remain in the analysis if important
variables are omitted from the procedure.
However, the results present a consistent
picture of increased HRQoL and work
productivity outcomes for DMF patients.
CONCLUSION
This study has highlighted the potential
advantages of using DMF therapy to treat MS
patients over ABCRE therapies (Avonex,
Betaseron, Rebif, Extavia, and Copaxone).
Higher HRQoL and work productivity
outcomes were observed in DMF patients than
in patients receiving an interferon or glatiramer
acetate therapy. The HRQoL outcomes were
used as a predictor of work productivity, which
demonstrated a positive correlation with the
EQ-5D and HAQUAMS measures, suggesting
that as HRQoL outcomes improve so does
productivity.
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